Radiopharm Theranostics Limited (ASX:RAD – Get Free Report) insider Riccardo Canevari acquired 684,787 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were purchased at an average price of A$0.03 ($0.02) per share, with a total value of A$19,858.82 ($12,411.76).
Radiopharm Theranostics Price Performance
About Radiopharm Theranostics
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
Featured Stories
- Five stocks we like better than Radiopharm Theranostics
- What is the Dow Jones Industrial Average (DJIA)?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Using the MarketBeat Dividend Yield Calculator
- 2 Drone Stocks Surging from Increased Media Attention
- How to Choose Top Rated Stocks
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
